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Abstract
There has been a rapidly growing area of research in the design and synthesis of
molecules that self-organize in water to form functional nanosystems and due to the high interest
in the area metal ligand complexes were tested as drug delivery systems with a Leishmania
vaccine. Herein, we present the design, synthesis and functional activity of Cu(II) and Zn(II)
complexes that self-assemble in water to form spherical nanoscale structures that exhibit an
affinity to bind DNA and deliver it into eukaryotic cells with a high percent efficiency in-vitro.
In order to assess the effectiveness of these nanoparticles to deliver DNA vaccines in-vivo, we
investigated the ability of the Cu(II) and Zn(II) complexes to bind and deliver a gene vaccine
against Leishmania mexicana challenged with Leishmania major, into mice models. Comparison
of the efficacy of these molecules will be discussed in regards to preventing murine
leishmaniasis infection.
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Chapter 1. Introduction.
1.1

MOTIVATION
Leishmaniasis is a tropical parasitic disease caused by a number of different parasite

species belonging to the genus Leishmania. It is a public health problem of global importance.
Worldwide, there are approximately 12 million people affected, 1.5-2 million new cases each
year, and 350 million at-risk for developing leishmaniasis. It is endemic in 88 countries on five
continents including 22 countries in the New World and 66 in the Old World. The incidence of
leishmaniasis is increasing in many regions of the world as the result of decreased
immunocompetence associated with HIV-AIDS, deforestation of primary rainforests, increased
overseas travel and military deployment to endemic areas. Leishmaniasis is considered a threat
to the military readiness of coalition forces serving in the Middle East. For example, in 2005
CDC has reported over 600 confirmed cases of the cutaneous form of leishmaniasis (CL) in U.S.
soldiers deployed to Afghanistan, Iraq, and Kuwait, with many more cases suspected.
The complex epidemiological characteristics of the disease and its transmission have limited
the success of disease control efforts in endemic countries. In addition, the conventional
treatment of CL with meglumine antimoniate, an antimony-based drug, is associated with
cardiovascular-, hepato- and reno-toxic side-effects. The development of a vaccine candidate that
elicits a strong and long lasting CD4+ and CD8+ cytotoxic T lymphocytes against Leishmania
could represent a significant advance. Prior authors have reported varying levels of protection
against leishmaniasis using a whole killed parasite approach6,7 or recombinant antigen vaccines.
More recently, investigators have begun to focus on the development of DNA vaccines for
leishmaniasis to prevent the disease. Finding a candidate vaccine for leishmaniasis is an
ambitious goal but many will benefit from it if accomplished.
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1.2

OBJECTIVES
The literature suggests that weak immunogenicity is the main obstacle for developing an

effective DNA vaccine. Prior studies indicate that the immune response produced by naked
DNA is insufficient to protect against the disease. Various attempts have been made to overcome
low DNA vaccine immunogenicity (efficacy). Studies in our lab have showed that metalloliposomes (ML) have low toxicity and bind DNA more efficiently and therefore have been
utilized as DNA delivery systems for the vaccine.
I hypothesize that encapsulating DNA vaccine candidate within metallo-lipid micelles
helps to avoid DNA degradation from surrounding DNAses prior to reaching target cells.
The first objective was to determine the efficacy of p-Vax-BT-ICAM, and/or p-Vax-ORFFAmastin plus metallo-liposomes in preventing murine leishmaniasis infection. The second
objective was to determine if metallo-liposomes possess adjuvant properties that enhance the
innate immune response.

1.3

BACKGROUND
Gene therapy is increasingly growing in its efficiency especially when presented with the

task of constructing methods for the delivery of DNA into mammalian cells. Viral vectors are
most commonly used in gene therapy but unfortunately pose many problems such as producing
undesired side effects, targeting the wrong cells in the body, and/or not guaranteeing that no
genes will be affected that are already present in the genome. Currently, viruses have been
genetically altered to encapsulate and deliver the desired genes to human cells in a pathogenic
manner. Other vectors employ the non-viral method, which consists of transfections and gene
expression. The use of naked DNA is one of the simplest methods of non-viral transfection in
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gene therapy. Naked DNA does not contain histones and therefore does not contain chromatin,
making the unwound DNA in chromosomes very long. In DNA vaccines or gene immunization
the term “naked DNA” is described as DNA that is free of any agents, allowing for transfection
capabilities. Transfection differs from transformation in that the DNA is simply expressed and
not necessarily incorporated in the cell’s genome; the DNA is only introduced into cells using a
vector or another method of delivery. Transfections allow the uptake of foreign material to enter
the cell by opening the transient pores in the cell’s membrane and allowing genetic material,
proteins, or antibodies to enter.
DNA vaccines have been applied to numerous viral, bacterial, and parasitic models of
disease. The DNA vaccination technique is utilized to protect an organism against disease by
injecting it with genetically engineered DNA to produce an immunological response. It is
termed genetically engineered because it employs techniques of molecular cloning and
transformation to alter the structure and characteristics of genes directly. DNA vaccines have yet
to be perfected but do have many advantages including their ability to induce a much broader
range of immune responses. Vaccines are characterized under generations; DNA vaccines are
labeled as third generation and consist of small, circular fragments of bacterial DNA called a
plasmid that is manipulated and genetically engineered to exhibit antigenic properties from a
protein belonging to a microorganism. When the vaccine is injected into a body’s cells the host
cells proceed to “read” the DNA and convert it to pathogenic proteins. Once the host cell has
processed the information, the proteins are recognized as being foreign and that in turn triggers
immune responses by activating the immune system.
Two types of immune responses exist, one being humoral immune responses and the
second being cellular immune responses. In a humoral immune response, the secretion of
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antibodies produced by B lymphocyte cells mediates immunity. The secreted antibodies bind to
the surface of antigens caused by a virus or bacteria and signals for their destruction. On the
other hand, a cellular immune response does not involve antibodies but the activation of
macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocyte cells, and the
release of cytokines in response to the antigen. The activation of antigen-specific citotoxic Tlymphocytes induces apoptosis in the cell’s body displaying epitopes of foreign antigen on their
surface, such as cells with intracellular bacteria. The activation of macrophages and natural
killer cells enable them to destroy the intracellular pathogens and stimulate the cells to secrete
the cytokines that influence the function of other immune cells. Cell-mediated immunity targets
those microorganisms that are able to survive in phagocytes and participate in the defense from
protozoans.
Phagocytic cells play a crucial role in the immune system by ingesting and destroying
microorganisms.19 A variety of different phagocytic cells exist such as blood
polymorphonuclear leucocytes, (neutrophils or granulocytes), which are able to respond to sites
of infections by migrating to the area. Monocytes are also found in the blood stream and become
macrophages once they leave the circulation and penetrate tissues. Some pathogenic
microorganisms are able to survive and replicate even after being ingested by macrophages,
which hinders the treatment. Defense mechanisms and antibiotics are unable to reach these
pathogenic microorganisms due to their intracellular location.13,29
Some pathologies that are caused by intracellular microorganisms include Leishmaniasis,
tuberculosis or histoplasmosis, among others. These intracellular microorganisms cause more
complications such as opportunistic infections especially in immunosuppressed patients. These
patients are more susceptible since the compromised immune system presents more of an
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opportunity for the pathogen to infect.48 Aminoglycosides, fluoroquinolones, beta-lactams, and
macrolides are among the most commonly used antibiotics in treatments of this type. These
antibiotics have been characterized as having different abilities to penetrate phagocytic cells,
possibly limiting their efficacy to treat intracellular infections.
The process of phagocytosis involves the ingestion of microorganisms by the cell
followed by their destruction and elimination. This process is similar to those seen performed by
macrophages and neutrophils. The phagocyte begins the process by forming a vesicle or
phagosome once it uptakes the microorganism with the aid of surface receptors that are
occasionally mediated by antibodies. The vesicle then fuses with the lysosomes, giving rise to a
phagolysosome. Macrophages produce bacterial agents such as cationic proteins and nitric oxide
to assist in the process; neutrophils produce derivatives of oxygen and halogen ions.27,59
Germs at times have the ability to bypass immune mechanisms by preventing fusion of
the phagosome and lysosome or by withstanding microbiocidal mechanisms in the
phagolysosome. These germs are able to survive in cellular compartments or in the cytoplasm if
they are able to cross the membrane successfully.2,59 The intracellular location serves as a
protective barrier from host defense mechanisms, such as antibodies and their activity.13,29
Because they can prevent the action of antibiotics by penetrating in cells and exiting the host cell
when levels of the antibiotic are low enough, it makes it quite difficult to treat these infections
and causes further relapse in patients.13,43
Phagocytic cells also have the capability of releasing drugs by way of chemotactic
mechanisms from the blood or tissues to the site of infection. It is important to recognize that the
antibiotic must have the capacity to become concentrated within the phagocytic cells in order to
combat against the extracellular microorganisms located at the site of inflammation or
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infection.22,25 The majority of antibiotics administered to the organism remain in the
extracellular space when they are needed to reach inside cells. Because the desired concentration
is unable to penetrate inside the cells, efficacy against intracellularly located pathogens in-vitro
show little or no antibacterial activity in-vivo even when high concentrations of the antibiotic
drug is present.56 Fluoroquinolones, beta-lactams and macrolides are able to penetrate cells
through diffusion or in the case of aminoglycosides by receptor-mediated uptake.13
Carrier systems must also possess certain characteristics especially if being utilized for
delivery of antibiotics to phagocytic cells to increase cellular penetration for the treatment of
intracellular infections. Not only should carrier systems remain stable under the in-vivo
conditions in which they are to be used but also must be quickly recognize and withdraw from
the circulation by the phagocytic cells of the reticuloendothelial system (RES) where the
pathogen is present in order to reach the desired concentration levels in the target cells. In order
to achieve therapeutic levels at the infection site over a duration of time, they must sustain the
drug for continuous release. They must decrease the possibility of side effects by preventing the
drug from manifesting its toxicological actions until the RES has been reached. Premature
degradation and immunological reactions should also be prevented while at the same time
maintaining drug retention in tissues. Most importantly, they must maintain the therapeutic
efficacy of the drug while decreasing its toxicity.

1.3.1 Leishmania major
Drug delivery systems have been employed in many intracellular pathogenic diseases but
have yet to be successful in treating the infections due to poor efficiency in the drug delivery
systems and high toxicity levels of the treatment itself. Leishmania major, an intracellular
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parasite continues to pose challenges in its treatment. Leishmania major is a protozoan parasite
from the family Trypanosomatidae which causes large skin lesions that take long periods of time
to heal. This parasite is of increasing interest because it is slowly moving northward from South
America into the United States. According to previous studies, it is estimated that Leishmania
infects approximately 5 million people worldwide and 350 million people live in areas were
leishmaniasis is endemic.49

Figure 1.1. Microscopic view of Leishmania parasite.41

Not all of the single celled parasites infect humans; the word Leishmania refers to a
genus of parasites that includes many different species, some of which target rodents.
Leishmaniasis is the name of the actual disease that is caused by these parasites; there are many
types of species that have been identified. Leishmania major causes cutaneous lesions and is the
least lethal specie that is gradually entering the United States, specifically Texas, from Central
and South America. Cutaneous leishmaniasis of the Old World (OWCL) is normally caused by
three species of leishmania: L. tropica, L. major, and L. aethiopica. Cutaneous leishmaniasis of
the New World (NWCL) is caused by numerous species and subspecies of Leishmania. The
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clinical features are similar to those of Old World cutaneous leishmaniasis but the lesions tend to
be more severe and chronic.
Three forms of leishmaniasis have been classified – cutaneous, mucocutaneous, and
visceral. Cutaneous leishmaniasis is a skin disease where the Leishmania parasite replicates
itself in the skin causing an ulcer that does not heal or takes months to do so. It is quite common
for a bacterial infection to follow after contact with the parasite. Mucocutaneous leishmaniasis
targets the mouth, nasal passages, pharynx and genitals. If left untreated the lesions in the
mucous membranes can result in deformities and may lead to serious complications that may
result in death. The most serious form of the disease is visceral leishmaniasis, which causes
severe damage to the immune system by proliferating in internal organs and tissues. Victims that
do not receive treatment for the disease die within three years of the initial onset of symptoms.

1.3.2

Parasitic Life Cycle
All species of leishmaniasis follow the same parasitic life cycle and alternate between

two distinct lifestages, the promastigote and the amastigote. Leishmania parasites are
transmitted to humans by the bite of an infected sand fly. The cycle varies in duration from 4 to
18 days according to the species of the infection and begins when motile promastigotes are
transmitted by Phlebotomus (OWCL) and Lutzomyia (NWCL) sandfly vectors to the mammalian
host. In order for the cycle to successfully progress forward, cool and low temperatures are
required, since high temperatures tend to shorten it.70 During the initial bite, the sand fly feasts
on human cells that contain the oval, microscopic, protozoan Leishman-Donovan bodies (or
amastigotes). The amastigotes enter the fly gut where they mature into the promastigotes, and
attach to the gut wall. Promastigotes are quickly engulfed by phagocytic cells at the site of
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infection, but only differentiate into the obligate intracellular amastigote in response to the acidic
environment of the macrophage phagolysosome.4,26 Promastigotes are significantly larger than
amastigotes with a long whip-like flagellum attached at one end.

Figure 1.2. Leishmania parasitic life cycle.51

The promastigotes multiply by way of binary fission, which allows their nuclear material
to divide in two, soon multiplying in large numbers in the fly’s gut. Before moving to another
host, the promastigotes are expelled by the sand fly as they become lodged in its esophagus
where it then releases them into its victim during a meal. They begin to invade host cells, often
macrophages, where they transform to amastigotes and begin the process once more. When
human macrophages become packed with amastigotes they rupture and are destroyed, releasing
themselves into new cells and tissues causing lesions. Leishmanial infections all share a
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common histological feature – the early accumulation of mononuclear phagocytic cells (or
hyperplasia) in the site of infection.

Figure 1.3. Leishmania parasites in sandfly midgut.44

The balance between parasite multiplication, the degenerative changes, and immune
response of the patient all impact and determine the clinical form of the disease. The chronic
symptom of the disease is due to the ability of the amastigotes to evade host macrophage cells
and persist for long periods of time in the host.3 Host complement receptors CR1 and CR3,
assist in the entry of Leishmania into macrophage cells without triggering oxidative burst.
The host-parasite relationship was not fully understood for many years but now it is
known that within the host macrophages, leishmanial amastigotes are safely protected from
antibodies and any substance that may be near the target tissue and that may be harmful to the
parasite.70 It is therefore crucial for the microorganism to become incorporated in the cells in
order to ensure parasitic survival. Parasite infested phagosomes fusing with lysosomes do not
seem to harm the parasites that eventually multiply in the phagolysosomes. Studies done in-vitro
have shown to induce an increase in oxygen uptake when there is phagocytosis of Leishmania in
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macrophages. Following the process of oxygen uptake, oxygen metabolites such as oxygen
peroxide are generated. Generally promastigotes are unable to withstand these compounds and
are destroyed in macrophages, however, in intracellular infections of this kind they are able to go
on and replicate themselves within the macrophage.
When the parasite has successfully invaded the tissues and has begun the process of
destruction at the site, oedema in the superficial dermis and damage to collagen and elastin is
usually seen, followed by fibrosis.70 In severe cases, there is necrosis of collagen or epidermis.
Capillaries at the site may show endothelial swelling or proliferation, and often there is vasculitis
leading to inflammation of the wall of blood vessels including veins, arteries, and capillaries due
to leukocyte migration and resultant damage.

1.3.3 Available Treatments
There is no known prophylactic vaccine available for leishmaniasis but several
pentavalent antimonials are available: sodium stibogluconate (Pentostam ®, GSK, United
Kingdom) and its generic forms, used in field conditions, and meglumine antimoniate
(Glucantime ®, Aventis, France). Old World localized cutaneous leishmaniasis requires local
infiltration with pentavalent antimony. The World Health Organization (WHO) recommends an
injection of 1-3ml under the edges of the lesion and the entire lesion until the surface has
blanched; injections should be administered every 5-7 days, for a total of 2-5 times.11 It was
reported in 1999 that intra-lesional antimonials partially or completely cured 72-97% of the
lesions caused by L. major. In a separate study done in Tunisia adverse events were observed in
5%, which included bacterial super-infections; it was seen most commonly in patients with
cutaneous leishmaniasis in the face or limbs.47 Other intra-lesional injections of hypertonic
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sodium chloride solution of zinc sulphate have shown to be effective as well as local sodium
stibogluconate in some Iraqi patients.64
Another treatment option is the use of paromomycin (aminosidine) which is an ointment
used in amoebiasis, intestinal helminthiasis or visceral leishmaniasis. It belongs to the
aminoglycoside family of antibiotics that is virtually identical to neomycin. Both compounds
contain a 2-deoxystreptamine attached to three aminosugars, the difference lies in the
substituents. Paromomycin has a CH2OH substituent on one of the aminosugars, whereas
neomycin has a CH2NH2 substituent.57 Even though these two compounds are nearly identical,
only paromomycin has antiprotozoal activity. Topical treatments available for cutaneous
leishmaniasis include a 15% paromomycin sulphate dissolved in a soft white paraffin base, either
with 12% methyl-benzothenium chloride or with 10% urea.10 A separate study showed that L.
mexicana infected mice were treated with paramomycin sulphate 15% + 12% methylbenzothenium chloride and proved to be effective but unfortunately failed to produce results in
68% of 53 Belizean patients infected with the same species.68 A similar study was conducted in
Guatemala where 76 patients infected with L. braziliensis (75%) and L. mexicana (25%) were
treated with 15% paromomycin sulphate plus 12% methyl-benzothenium chloride for 20 days
resulting in an initial cure rate of about 91% but after a one year follow up study was conducted,
their progress declined to 86%.5
Another method used to treat cutaneous Leishmania is through an FDA approved device
called ThermoMed ® which targets the lesions directly by delivering localized radiofrequencygenerated heat through prongs that are placed onto the infected site. Most sessions require
heating at 50 °C for 30s and local anesthetic due to the painful procedure. Guatemalan patients
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with L. mexicana induced cutaneous leishmaniasis experienced similar effective results when
using meglumine antimoniate as with the localized controlled heat.52
The first major attempt at liposomal therapy involved the encapsulation of a pentavalent
antimony. Alving et al. conducted the study and composed the liposome utilizing dicetyl
phosphate, cholesterol, and diplamitoylphosphatidylcholine.57 The preparation of the liposome
involved adding the drug to lipid solubilized in chloroform, followed by the evaporation of the
chloroform. The formulation of the liposome was not considered for clinical use due to its high
toxicity; dicetyl phosphate is not a compatible bodily constituent and may be toxic once
administered and also, there is no guarantee that the evaporation process of chloroform will
remove it entirely.57
The second major attempt was directed towards developing a liposomal delivery system
that was less toxic but just as effective at combating the infection. Lopez-Berestein synthesized
a liposome composed of dimyristoylphosphatidylcholine and
dimyristolyphosphosphatidylglycerol (7:3) containing amphotericin B (10% by weight).57 The
researchers’ main concern was for the liposome to be maintained in circulation once in the body
and avoiding the removal of it by the kidneys. It was hoped that it would bound to free fungi and
to fungi within the host cells and in the process would decrease the amphotericin B resulting in
an increase in activity.57 Clinical studies showed that patients were able to tolerate up to 5 mg of
Amb in the form of liposome/kg/d, the normal maximal dose was actually determined to be 1 mg
Amb (free)/kg/d. Clinical studies of the liposomal preparations are currently underway and are
available for trial as anti-leishmanial agents. The safest and best preparation of the liposomes
involved determining which method would lead to the least accumulation of the drug in the
kidneys, liver, spleen, and bone marrow.
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1.3.4 Vaccine Candidate
At the present the only known and effective immunizing intervention for preventing
cutaneous leishmaniasis caused by L. major in humans is Leishmanization (LZ).54 LZ is
accomplished by injecting the live virulent parasite in healthy individuals. LZ is no longer being
practiced in countries such as Iran and Israel since the 1970s and 1980s.
In Brazil, investigators prepared killed parasites for trials in 1939 and was followed by
the evaluation of the polyvalent vaccine of 18 strains of Leishmania in the 1940s. This progress
was a stepping-stone for Mayrink and coworkers in the 1970s when they developed a pentavalent
vaccine.54 The efficacy of the vaccine could not be assessed since no cases occurred in the study
after vaccination in either the vaccine or placebo group. Mayrink and coworkers continued their
studies in 1981 and 1983 when they administered controlled trials of the pentavalent vaccine
using different doses in Brazilian army personnel.54 Unfortunately, the trial results did not show
a significant difference between the vaccine and the placebo arms.
There has been only one leishmaniasis vaccine in which efficacy was observed in the
entire vaccinee’s cohort and was conducted by Armijos et al. in Ecuador.6,7,54 Safety,
immunogenicity and efficacy of two intradermal doses of a locally prepared trivalent vaccine
were assessed against two doses of Bacille Calmette-Guèrin (BCG) adjuvant. Promastigotes of
L. braziliensis, L. guyanensis, and L. amazonensis were originally collected from the lesions of
patients living in the study area and were mixed with BCG (prepared from a strain of the
attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, that has lost its
virulence in humans by being specially cultured in an artificial medium for years) to construct
the vaccine.6,7,54 The vaccine was shown to be safe after a 12-month follow-up with a 2.1%
incidence of CL in the vaccine arm vs. 7.6% in the control arm, resulting in an efficacy of 73%.
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Patients were followed up for another 4 years and although the protective efficacy was still
significant between the 13th and 18th month, it was not after the 19th month follow-up. Total
incidence from the 19th to the 60th month was not significantly different between the vaccine and
control arm subjects who were followed up.6,7,54 The loss of the statistical significance is thought
to be due to the reduction in the number of new cases in the control group and not due to an
increase in the number of cases in the vaccine arm.6,7,54
In Iran, one injection of a vaccine was compared with one injection of BCG alone in a
randomized, double-blind, controlled field efficacy trial of autoclaved L. major (ALM) + BCG
against CL due to L. major.54 Volunteers ranged in age from 5 to 72 years and were healthy,
leishman skin test (LST) negative residents. The leishman skin test measures delayed type
hypersensitivity reactions to an intradermal injection of a suspension of killed promastigotes.
After 2 years of follow-up there was no significant difference in the leishmaniasis incidence rates
in the two arms and infection rates among LST converted individuals (both in the vaccine and
the control arms) were lower than in those whose LST had not converted (7.3% vs. 11.3% in the
vaccine arm and 3.4% vs. 10% in the control arm).54
Protective efficacy has not been seen in many clinical trials of first generation
leishmaniasis vaccines except for those constructed by Armijos et al.6,7,54 Even though efficacy
has only been shown to be present in one vaccine, prophylactic findings discussed above show
very encouraging results. This study is unlike any other attempted before in that previous
vaccines used BCG as the adjuvant and this investigation is the first to implement metal ligand
complexes to improve DNA delivery.
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Chapter 2. Metallo-Lipid Nanoparticles for Drug Delivery Systems.

2.1

DRUG DELIVERY SYSTEMS FOR INTRACELLULAR INFECTIONS
Because one of the biggest obstacles in producing a treatment for intracellular infections

is determining an efficient and effective method for the delivery of the drug to the targeted site,
all options must be presented that may serve as possible candidates as a delivery system. Many
of the recently explored techniques include the use of micelles, nanoemulsions, nanoparticles,
and liposomes. While they may all have their advantages and distinct capabilities, one method
has yet to be proven effective, at least for the treatment of leishmaniasis. Micelles,
nanoemulsions, nanoparticles, and liposomes have been continuously investigated for their drug
delivering capabilities.43 As stated by Husseini,30 targeted drug deliver is essential to modern
medicine in which specifically designed and effective drugs are employed to work on selected
tissues, cells, and cellular structures. In the end, it would be ideal to localize the delivery of the
drug to a specific organ instead of systemically injecting and exposing the entire body to the
potentially toxic drug and at the same time use less of the costly drug.

2.1.1 Micelles as Drug Delivery Systems
Micelles have recently played a dynamic role in chemotherapy treatments and have been
found to have applications as drug delivery systems. A micelle is an aggregate of surfactant
molecules dispersed in a liquid colloid. Micelles take on various shapes and are of different
sizes. A normal phase micelle, which is a typical oil in water micelle, forms an aggregate with
the hydrophilic “head” regions that are in contact with the solvent in aqueous solution,
sequestering the hydrophobic tail regions in the micelle center. Others have the head groups at
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the center with the tail extending outward, these are referred to as inverse micelles. Micelles, for
the most part, are spherical in shape although some are ellipsoids, cylinders, and bilayers.
Surfactant concentration, pH, temperature, as well as ionic strength determine the shape that the
micelle will exhibit.
Polymeric micelles have been the focus as drug delivery vectors. They are formed by a
spontaneous assembly from amphiphilic polymers in selective solvent to decrease their free
energy and are of great interest since they are thought to water-solubilize hydrophobic drug
molecules. Their structure and 10-100 nm size allows them to be sterilized by simple filtration
and avoid mechanical clearance by filtration in the spleen.16 Because they are smaller than 200
nm they are ideal particles for systemic administration for a long-circulation drug carrier, and
therefore are difficult to be recognized and internalized by the reticuloendothelial system (RES)
because of their hydrophilic shell. This is of extreme importance since the RES consists of
mostly phagocytic, monocytic, and macrophage cells located in the reticular connective tissues
which help initiate specific immune mechanisms in the body by phagocytosing cellular debri and
pathogens. Micelles also have the capability of storing indissolvable drugs to increase their
solubility. When referring to chemotherapy applications, micelles with small size and long
circulation are easily accumulated at the tumor site due to their enhanced permeability and
retention (EPR). When utilizing micelles for therapeutic use, researchers suggest that
administration of drugs should be combined to increase efficiency of the treatment instead of
encapsulating one single drug.
Chemical conjugation is another method of incorporating drugs into micelles.
Copolymer-drug conjugates are the result of covalent coupling of the drug to the hydrophobic
block of copolymers.73,74,75 Conjugates in the form of micelles have been found to circulate the
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blood much longer than when introduced in free drug form. Studies performed by Kwon et al.
showed that lower levels of conjugate were detected in major organs, whereas a much higher
conjugate level was found at the site of the target, in this case being the tumor.12
Unfortunately, most micellar carriers exhibit a rapid clearance from circulation after
administration by way of endocytosis, phagocytosis, and liver uptake.68 A method by which this
can be resolved is by incorporating an exterior layer of poly ethylene oxide which results in the
modification of the micelle surface, preventing them from being cleared from circulation as
easily. Micellar drug carriers are able to remain longer in the blood circulation because they go
undetected and are protected due to water association with the PEO chains, leading to steric
repulsion of proteins and a decrease in protein adsorption on the surface of the drug vehicles.
Other researchers have found that an increase was seen in the concentration of encapsulated drug
in the blood, leading to an increase in drug concentration in tumors when PEO chains were
incorporated in the design of the drug delivery systems.68

2.1.2

Nanoemulsions as Drug Delivery Systems
Emulsions are a second drug delivery system candidate that are defined as a mixture of

two immiscible (unblendable) substances where one substance, referred to as the dispersed
phase, is dispersed in the other, and is referred to as the continuous phase. In emulsions a
surfactant stabilizes the system to prevent the dispersed phase from coalescing in a macroscopic
phase.61 In drug delivery systems, the drug being delivered is transported or is itself the nonaqueous liquid phase of the emulsion and many times, the continuous phase is the aqueous
phase. In many cases, it is common to see hydrocarbons or fluoro-carbon liquids acting as the
dispersed phase, carrying a hydrophobic drug that will be transferred to the target cells and
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tissues by a disruption or the dissolving of the nanoemulsion carriers, causing a quick release for
the drug transfer. Therapeutics can be slowly delivered by diffusion while utilizing a more stable
emulsion.

2.1.3 Nanoparticles as Drug Delivery Systems
Nanoparticles differ from emulsions in that they consist of a solid core or form a
macroscopic solid at room temperature and may not necessarily be spherical in shape. A vast
array of solid nanoparticles are employed and used in drug delivery.58 The advantage of
polymeric nanoparticles is that they consist of non-soluble polymers that allow them to release
drugs as they degrade or can release the drug from the polymeric core by diffusion. Once the
nanoparticle has been formed, covalently crosslinking the polymer will sustain its structure so
that it does not dissolve in water or blood and proceed into forming hydrogel nanoparticles that
are soluble or amphiphilic polymers that are capable of carrying the drug. A dendrimer is
another type of polymeric drug carrier that allows for drugs to be attached to its highly branched
polymer arms or that sequesters them and releases them by diffusion.
Other nanoparticles that are non-polymeric have also been researched as drug delivery
systems. Nanotubes and fullerenes consisting of graphitic carbon can carry drugs within their
volume or if attached to their tubular or spherical cage-like surface.37 Other examples include
aggregates of hydrophobic proteins or drugs that have the potential to partially crystallize into
nanoparticles. Nanoparticles that consist of a solid lipid core that can carry a hydrophobic drug
stabilized by an external monolayer of steric or charged surfactant are referred to as solid lipid
nanoparticles.
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Compared to liposomes, nanoparticles have greater encapsulation efficiency, greater
stability in the presence of serum and during storage, as well as the ability to achieve sustained
release.9,55 Along with their advantages, they can also affect biological behaviors at the cellular,
subcellular, and protein level. Because they are so small in size, they can easily be distributed
throughout the body, reaching target tissues and sites in the cell that are of delicate nature such as
the nucleus or mitochondria, leading to genetic damage and mutations.53,58 Nanometer size
polymers are not ideal as nanoparticles because they are taken up by cells and are degraded
inside them, with the possibility of causing cytotoxic effects.50,58
As mentioned above, hybrids between polymeric microparticles and liposomes, are
known as solid lipid nanoparticles (SLN), and have the advantages that fatty emulsions and
polymeric nanoparticles exhibit.21 Because they consist of a solid matrix composed of lipids
stabilized in the form of aqueous suspensions by a surfactant covering, they have proven to be
adequate for the encapsulation of lipophilic drugs. In a study, it was shown that SLNs are less
toxic than polymeric microparticles when analyzed in a culture of human granulocytes.50 They
too have shown to have the ability to degrade faster and have better control when releasing a
drug at the site of infection.18,28,35,39

2.1.4 Liposomes as Drug Delivery Systems
Liposomes are classified by their phospholipid bilayers that surround an aqueous
compartment, they are simply defined as microscopic vesicles. Liposomes are classified as
either single-layer vesicles (SLV) or multilayer vesicles (MLV). Their overall structure is
composed of phospholipids, cholesterol, and may contain other lipids and proteins. They are
widely known for their ability to encapsulate hydrophilic drugs in aqueous phase due to their
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range in size from 25nm to several microns. Hydrophobic drugs are able to be bound to the lipid
bilayer for delivery as well. Some of their advantages include their low toxicity and their ability
to biodegrade.
Liposome toxicity varies depending on cell types. For example, liposomes composed
with cationic liquids were shown to be toxic to phagocytic macrophages and monocyte-like cells,
but not to nonphagocytic T lymphocytes.21 Other different liposomal formulations led to
symptoms of neurotoxicity in experimental animals.1,72 It is therefore extremely important to
take into account the choice of the main lipid and the charge component to minimize the toxicity
as much as possible.
Liposomes have the ability to quickly be removed from circulation by monocytes and
macrophages and accumulate in the major organs, this in turn is an important attribute when
working with intracellular infections. A mechanism exists describing the steps taken during the
penetration of liposomes by phagocytic cells. The first step in the process requires a stable
adsorption on the cell membrane, followed by the vesicle being internalized through an energy
dependent mechanism and the fusion of the endocytic vesicles with the lysosomes. Before the
drug can be released, the liposome must be degraded by lysosomal enzymes.2,33 This proves to
be an ideal treatment when germs from infections are present in the lysosome but is not a useful
treatment if they are residing in the cytoplasm. When the germs are located in the cytoplasm, pH
sensitive liposomes are used, liposomes of this nature will destabilize the lipid bilayer due to the
decrease in pH in the endosome, allowing fusion of the liposome with the endosomal membrane,
thus releasing the drug in the area.15,45,67
In order for liposomes to successfully reach the site of infection and release the drug a
number of conditions must first be met. They must bind to and be phagocytosed by
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macrophages and most importantly maintain the encapsulation of the drug as well as prevent its
degradation before reaching the target tissue. Once these conditions have been met, liposomes
must make their way to the organ where the infection is localized.2 The infection site is abundant
with macrophages and in order for liposomes to penetrate into these macrophages their size,
composition, cholesterol content, and surface properties of the lipid bilayer must be taken into
consideration.
Liposome nanoparticles have been documented as promising candidates for having
adjuvant properties and being carrier systems for antigen delivery.70 Liposome based adjuvants
can be manipulated to increase immune responses by modifying chemical derivatization of the
lipid, conjugation of ligands or polymers on the surface of the liposome, or by implementing
other modulator molecules to the interior compartments of the liposomes.70
2.2

COPPER AND ZINC LIPID NANOPARTICLES
Recently, metal-mediated supramolecular complexes have been synthesized that are able

to successfully deliver large fragments of DNA into eukaryotic cells. As cited from Arroyo, the
molecular design consists of the formation of amphiphilic Cu(II) complexes that self-assemble
into metallo-liposomes in water and condense DNA plasmids into deliverable structures
programmed to react with intracellular components via redox- and ligand-exchanged reactions.
Marine bacteria and other organisms consist of natural coordination-capable lipids allowing them
to self-assemble into micelles in water and upon binding to transition metal ion, forming metalloliposomes as they undergo phase transitions. These siderophores have been utilized to study
electron-transfer reactions across membranes.
Prior studies have shown that these synthetic amphiphiles with coordination-capable
head-groups are able to self-assemble via coordination interaction (first generation assembly)
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and by hydrophobic-hydrophilic interactions of the amphiphiles (second generation assembly).
These molecules have been referred to as coordination amphiphiles. These molecules were
designed to self-organize via coordination and hydrogen bonding interactions into molecular
ensembles ranging in sizes between 10 nm or smaller in aprotic solvents. Coordination
amphiphiles that have the capability of forming liposomes or vesicles result in nanosphores
composed of amphiphilic bilayers that are able to separate from the bulk aqueous phase into an
aqueous internal compartment that range in size between 50-500 nm.

2.2.1 Ligand Design
When selecting a ligand, it was extremely important that it possess the capability of being
functionalized with hydrophobic alkyl chains while sustaining its ability to produce coordination
interactions with transition metals. 1,4,7-triazacyclononane (TACN) was chosen due to its three
secondary amines capable of being modified with hydrophobic groups and because of its Lewis
base character.

Figure 2.1. Chemical structure of the ligand 1,4,7-triazacyclononane (TACN).

2.2.2 Synthesis of alkyl modified triazacyclononane ligands with coordination complexes
In recent studies, lipids forming bis-complexes with Cu(II) ions, namely
[Cu(II)(Ldt)2](OTf)2 and [Cu(II)Lot)2](OTf)2, where Ldt = 1-dodecyl-1,4,7-triazacyclonone, Lot =
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1-octadeceyl-1,4,7-triazacyclonone, and OTf = trifluoromethanesulfonate have been synthesized
having coordination capabilities. The ligands were prepared from corresponding nucleophilic
addition of one equivalent of 1-bromoalkane to 1,4,7-triazacyclononane (Ltacn) in dry THF over
sodium hydride at 60 °C for 12 h. After flash column purification, they were reacted with half
equivalents of Cu(OTf)2 in acetonitrile at room temperature to form corresponding amphiphilic
Cu-complexes which were isolated by fractional crystallization with diethyl ether at -40 °C. The
amphiphilic complexes self-assembled into metallo-liposomes in water and did exhibit an
affinity to bind the PO4 groups of DNA via electrostatic and hydrogen-bonding interactions.
A tridentate metal binding domain and a hydrocarbon (C12H37) group in the lipid ligand
1-dodecyl-1,4,7-triazacyclononane ( Lot ), allowed them to have amphiphilic properties. Upon
reactions with divalent transition metal salts, they formed bis octahedral complexes. In
particular, the Cu(II) bis-complex of Lot forms [Cu( Lot )2]2+ (1d), self-assembled into metalloliposomes with bilayer composition in aqueous media. Due to the cationic nature of the surface
of 1d and the hydrogen bonding motifs available, these metallo-liposomes had an affinity to bind
DNA strands. AFM experiments revealed that the most favorable interaction of 1d with DNA
was the formation of a surface complex that appeared to have a tetrahedral structure.
The alkyl modified triazacyclononane ligand was previously documented by Arroyo8 and
was used when reproducing the synthesis. Alkyl substituted triazacyclononane ligand containing
12 carbons in the alkyl chain were synthesized by the nucleophilic addition of one equivalent of
1-bromododecane to 1,4,7-triazacyclononane (TACN) in dry THF over sodium hydride at 60°
for 24 hours. Flash column using a gradient of chloroform-methanol was used to purify the
product.
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Figure 2.2 Synthesis of an alkylated derivated of TACN.

Synthesis of the amphiphilic coordination complexes followed, by reacting the alkyl
monosubstituted triazacyclononane ligand at room temperature for 24 h with one half of
equivalent of Cu(II)/Zn(II) triflate in acetonitrile in order to create a coordination amphiphile
with a complete coordination sphere surrounding the metal. Copper and zinc were ideal for the
synthesis due to their biocompatibility and coordination capabilities. The copper synthesis is not
shown or illustrated but same procedures were followed.

Figure 2.3. Synthesis of copper coordination amphiphile.
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2.2.3 Immunological Applications
As mentioned previously, DNA delivery systems have their share of disadvantages and
limitations due to their dependency on electrostatic interactions between positively charged
structures and the negatively charged DNA. Successfully transfecting mammalian cells with
exogenous DNA or RNA is an ambitious goal especially when considering the lack of treatment
options existing for Leishmania.
The copper and zinc amphiphiles that have been synthesized are hypothesized to bind to
phosphate groups in DNA via electrostatic interactions and hydrogen bonding due to their head
groups. It has been documented by Arroyo that the distance between two adjacent phosphate
groups is the same as the phosphate analogues (OTf) in the structure and therefore it is thought
that it was possible for the copper/zinc complex to bind to DNA using a hydrogen bond between
N-H…O where the N-H is the amine group of the ligand and the oxygen is part of the phosphate
group in the backbone of the DNA. Due to these findings, we have high expectations that the
head group will interact strongly with the DNA and therefore serve as an effective DNA delivery
system.

Figure 2.4. Electrostatic and hydrogen bond of the Cu lipid
complex with DNA.
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In order to ensure that there was encapsulation of the DNA, an agarose gel was treated
with SYBR green. The first well served as the control and was clearly showed that no DNA was
encapsulated due to the bands seen. The second and third well contained low volumes of the Zn
lipid-complex with 500 ng of DNA and it was determined that a higher volume was needed for
full encapsulation. The last two wells showed full encapsulation of DNA with higher volumes of
the Zn lipid complex. Same results were seen when the Cu lipid complex was tested for
encapsulation efficiency. For full encapsulation of the pVax-BT-ICAM plasmid, 65 µl of the Cu
lipid complex was utilized and 40 µl of the Zn lipid complex. The pVax-ORFF plasmid required
60 µl of the Cu lipid complex and 40 µl of the Zn lipid complex for full encapsulation of DNA.

Figure 2.5. DNA encapsulation with Zn lipid-complex.

In previous studies conducted by Arroyo,8 the material was tested for its ability to
transfect eukaryotic cells with DNA plasmids containing the reporter GFP gene, which encodes
for the Green Fluorescent Protein, an excellent indicator for gene expression. Originally the
highest transfection value observed with was 4%. However, efficiency was improved to 39 % by
changing the length of the hydrocarbon groups.
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Under the experimental conditions discussed above, the lipid metal complex, Cu(II) biscomplex of Lot forms [Cu( Lot )2]2+, which contained two n-dodecane groups, exhibited
comparable transfection efficiency to the well-established commercial transfection agent
lipofectamine (45%), Figures 2.6 and 2.7.

Figure 2.7. T291 cells transfected with
pEGFP-N1 plus metallo-liposome-Cu2+.
Expression of green fluorescent protein was
visualized.

Figure 2.6. T291 cell transfected with
pEGFPN1 plus metallo-liposome-Zn2+.
Expression of green fluorescent protein was
visualized.

2.2.4. Cytotoxicity Assay Study
U-937 cells were cultured in a 96-well microtitre culture plate using a cell suspension
adjusted to 2.5 x 105 cells/well. The metal ligand complexes were dissolved in PBS, which was
diluted to produce concentrations of 2, 4, 8, 16, 32, 64, 128, and 256 nM/well. Each experiment
included the different ligand concentrations, the solvent, an untreated control, and positive
control (pentamidine). These were added to their respective wells. Fresh culture media with the
ligand complex was replaced after 48 h of culture. After 54 h 1 µCi of [3H] thymidine was
added to each well; 18 h later [3H] thymidine incorporation was measured. All cultures were
performed twice in triplicate. LD 50 was determined to be 24 mM/24nM for both Cu and Zn
complexes.
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In summary, it was shown that transfection efficiency was comparable to the
commercially available Lipofectin when tested on COS1 cells. Encapsulation efficiency was
shown to for both Cu and Zn lipid complexes and may prove to be an effective DNA delivery
system.
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Chapter 3. DNA Vaccine for Leishmania major
The use of biopterin transporter (BT), cell adhesion molecule-like (ICAM-l), ORFF, and
Amastin Leishmania antigens as a prophylactic DNA vaccine constitute a novel approach for the
prevention of cutaneous leishmaniasis (CL) caused by Leishmania major using a Leishmania
mexicana antigen. The BT molecule of Leishmania was first described in Leishmania donovani
by Lemley and associates.42 Recombinant BT previously was found to confer partial protection
when used as vaccine candidate for preventing visceral leishmaniasis in a murine model. This is
the first attempt to use BT as a vaccine candidate to prevent CL in a mouse model.
To date, the ICAM molecule is the only of its kind found in Leishmania. It was first
described in L. amazonensis by Chiang.54 ICAM-l is located in the parasite nucleus and on its
surface. Previous studies characterized this molecule as a Leishmania ligant, which interacts
with receptors on phagocytic cells.54 Our study also is the first to use ICAM-l as a vaccine to
prevent CL in a mouse model. The ORFF molecule was first described by Myler and colleagues,
who suggested it had protein coding functions.54 Tewary showed that this molecule has been
shown to confer partial protection against murine visceral leishmaniasis.54 Finally, Amastin,
recently described by Almeida and associates belongs to an extended family of external surface
proteins on Leishmania.54 To date, no attempts have been made to utilize this molecule as a CL
vaccine candidate.

3.1

DNA PLASMID ANTIGENS
The L. major cocktail vaccine utilized for the inoculation of mice in this research consists

of two antigens (BT and ICAM) that will be expressed for the same plasmid. Five separate
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constituents construct the vaccine – BT, ICAM, ORFF, Amastin, and pVAX. The reason that so
many genes were utilized in the vaccine was due to the size of the parasite. Because, they are
large in size, minimal protection would exist from the use of only one gene and in turn would
make the parasite more viable and adaptable. If only one molecule was targeted in a parasite, the
parasite would continue replicating due to its inefficiency.
BT (biopterin transporter) is a gene responsible for encoding the transport of biopterin. It
is present in the promastigote and amastigote stages in the parasitic life cycle.24 The biopterin
transporter 1 (BT1), initially known as ORFG, is amplified in all strains of Leishmania. BT1 is
characterized as a membrane transporter that is found in Trypanosomatids. Research has found
that biopterin may be a potential growth promoter for Leishmania cells.24 The exact role of BT1
in Leishmania is unresolved but it is thought that pteridines must be acquired from a host in
order to uptake biopterin and therefore ensure the survival of the parasite.42
ORFF is one of two molecules that is responsible for adhering to the parasitic cells and is
thought to also be part of the amplification unit of the parasite.31 It is present in the promastigote
and amastigote stages of the Leishmania life cycle. The ORFF gene is localized 365-bp
upstream of the BT1 and is approximately 1086 nucleotides in size. The gene contains a Sadenoysl methionine (SAM)-dependent methytransferase motif.31,66 Like BT1, ORFF has been
shown to amplify all strains of Leishmania resulting in LD1 amplification and therefore an
advantage for parastitic survival.
ICAM is also a gene present in the promastigote and amastigote stages in the parasitic life
cycle and is located in the nucleus.24 In order for a vaccine to combat a parasite, the survival
mechanism of that parasite must be hindered. ICAM interacts with specific receptors in
macrophages that target the mechanism of survival and is responsible for adhering to parasitic
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cells. Microorganisms avoid phagocytosis, but in the case of Leishmania, it induces the process
since it requires for it to be engulfed by the macrophages in order to survive. Unlike T. cruzi that
is able to survive within the cytoplasm of a cell, Leishmania is unable to do so and therefore it is
crucial that it be phagocytosed. Leishmania contains enzymes that allow it to resist
immunological attacks and because it is unable to synthesize DNA bases, it requires a host in
order to obtain these bases to multiply and duplicate.
Amastin is specifically expressed in the intracellular amastigote stage of the parasite. The
Leishmania Amastin gene homologs contain four predicted transmembrane helices and are
localized within the plasma membrane of the parasites.24 As transmembrance proteins, Amastins
have the capability of catalyzing the specific transport of ions, metals, nutrients or metabolites
across the membrane barriers. Once in the phagolysosomes, most of the Amastin homologs are
expressed once the parasite is fully differentiated into its intracellular amastigote form.24 Being
able to survive inside the acidic environment of phagososomes requires the efficient transport of
water soluble molecules for parasite pH homeostasis and growth, and Amastins may play a role
in these proteins.
PVAX is an unstable plasmid. Because it is unstable, it is only temporarily present in the
cells. When constructing a vaccine, it is important and crucial to avoid incorporating foreign
DNA in another being. In the case of this vaccine, the genes are only being expressed
temporarily until the body is able to generate memory cells. Those cells will in turn fight the
parasite after a sufficient amount of memory cells are produced. PVAX is the only plasmid
approved by the FDA for human vaccinations due to its unstable properties that allow for its easy
removal from the body.
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Figure 3.1. pVAXBT-ICAM plasmid.

Figure 3.2. pVAXORFF-Amastin plasmid.

The above diagram represents the cocktail vaccine comprised of the antigens (BT, ICAM,
Amastin, and ORFF) where PCNV serves as the promoter for BT, ORFF, Amastin and ICAM and
is responsible to assure that BT and ORFF is expressed and read in ribosomes; IRES reassures
expression of ICAM and Amastin. NEH-I, BAM H1, PST-1 and XBA-1 are restrictive enzymes
present in the plasmid. BGHpA acts as the stop codon, whereas pUCORI is the start codon.
Kanamycin is present in order to segregate those cells that are able to become resistant to the
antibiotic from those that are not.

3.1.1 Transfection of COS1, Hela, and Macrophage Cell Lines
COS1 cells were transfected with the DNA plasmids in order to determine if the antigens
were being expressed to promote antibody activity. This was determined with the use of a
fluorescent tag. Cells were seeded on cover slips in 6-well plates at 2 x 105 cells/well in 3 ml of
DMEM and incubated at 37 °C in 6% CO2 until reaching 50-60% confluency. A final volume of
300 µl and 10 µl of plasmid DNA was mixed with 30 µl of Lipofectin (Invitrogen). Staining was
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performed by incubation in 1:100 diluted rabbit anti-BT or anti-ICAM-I antibody for 2 h at room
temperature. Cells were washed 4x with PBS and incubated for 30 min with goat anti-rabbit Igfluorescein isothiocyanate conjugate.

Figure 3.3. COS1 cells transfected with
pVAXBT-ICAM and incubated with anti-BT.

Figure 3.4. COS1 cells transfected with
pVAXBT-ICAM and incubated with anti-ICAM.

Figure 3.5. COS1 cells transfected with pVAXBTICAM and incubated with anti-ICAM, control.

Macrophages and Hela cell lines were transfected with mice serum and anti-antibody.
Cells were cultured on a 24-well plate at 106 cells/well with DMEM and incubated at 37 °C in
6% CO2 until reaching 50-60% confluency. Cells were fixed with fixation solution and
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incubated for 10 minutes. Cells were washed and incubated for 1 hour with mice serum. Cells
were washed once more before incubation with anti-antibody for 40 minutes.

Figure 3.6. Macrophages transfected with
BT/ORFF + Cu complex

Figure 3.7. Macrophages transfected with
BT/ORFF + Cu complex

Figure 3.8. Hela cells transfected with
BT/ORFF + Cu complex

Figure 3.9. Hela cells, control.

3.2

PARASITE
The Leishmania major promastigotes used in the study were maintained by successive

culture in RPMI 1040 media supplemented with 10% fetal bovine serum.
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3.3

DNA LEISHMANIA VACCINE CANDIDATE
The proposed study is a logical follow-up of research conducted in Ecuador, which tested

the effectiveness of killed, whole-parasite vaccine candidates. The current study protocol was
approved by the UTEP Institutional Biosafety Committee recombinant DNA Protocol (IBC) on
March 14, 2005 (protocol # 2005-02). The BT, ICAM, ORFF, and Amastin genes, shown to be
immunogenic in other Leishmania species, were PCR-amplified from the L. mexicana genome
and were inserted into the cloning site of pVAX1© (Invitrogen, cat No: V26020). A eukaryotic
expression vector, pVAX1© was specifically designed for DNA vaccine development following
FDA recommendations for plasmids used in DNA vaccines for preventable infectious diseases. It
is a 3 kbp plasmid which has CMV based promoter, bovine growth hormone polyadenilation
sequence and kanamycin resistance gene for selecting in E. coli. Therefore, it offers only those
sequences required for expression in order to minimize the possibility of chromosomal
integration and was recently shown to be an adequate carrier for non-viral vaccines. The novel
pVAX-BT-ICAM or pVAX-ORFF-Amastin products, containing the BT and ICAM-1 or ORFF
and Amastin reading frames are under the control of CMV promoter and IRES enhancer element
to yield the expression vector. It was inserted downstream of a kozak consensus sequence and in
frame with an initiation codon. The DNA was purified by ion exchange chromatography with a
Promega maxi kit.

3.4

IMMUNIZATION
All groups of BALB/c female mice were injected a maximum volume of 100 µl via an

intra-muscular route in the hind leg quadriceps using a one ml syringe with a 30 gauge, ½-inch
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needle (BD Ultra-Fine needle TM). The experimental groups were immunized with 100 µg pVaxBT-ICAM-l (group 1A), 100 µg pVax-ORFF-Amastin (group 2A), 100 µg pVax-BT-ICAMl/pVax-ORFF-Amastin (group 3A), 5 µg pVax-BT-ICAM plus 5 µg pVax-ORFF-Amastin plus
32 ng ML-Zn2+ (group 4A), 5 µg pVax-BT-ICAM plus 5 µg pVax-ORFF-Amastin plus 32 ng
ML-Cu2+ (group 5B), 5 µg pVax-BT-ICAM plus 5 µg pVax-ORFF-Amastin (group 6A), PBS
(group 7A), and 32 ng ML-Zn2+ (group 9) respectively.

Figure 3.10. BALB/c female mice groups.

3.5

Figure 3.11. Female BALB/c mouse entering
trap for immunization.

INFECTION CHALLENGE AND LESION MEASUREMENT
Three weeks after the third immunization, the mice were challenged subcutaneously in

the right hind footpad with 40 µl of 5 x 104 live stationary phase L. major promastigotes. The
development of footpads lesions (i.e., swelling) at the infection site were measured every week
using a digital caliper. The measurements were expressed as the difference between the thickness
of the infected versus contra-lateral non-infected footpad on the same experimental animal. As
weeks progressed, lesion measurements increased in inflammatory responses. Group 3A, which
were treated with the cocktail vaccine, induced the most protection when compared to individual
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plasmid molecules. BT and ORFF plasmids were shown to be less effective when individually
used.

Figure 3.12. Footpad lesion inflammatory measurements taken throughout an 7 week period after mice
were challenged subcutaneously with L. major parasite.
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Figure 3.13. Zn control (group 9) and PBS control
(group 7A) footpad lesion comparison at week 6.

Figure 3.14. PBS control (group 7A) and cocktail
vaccine footpad lesion comparison (group 3A) at
week 6.

Figure 3.15. Cu lipid complex + cocktail vaccine
(group 5B) and Zn control (group 9) footpad lesion
comparison at week 6.

3.6

IMMUNOLOGICAL MEASUREMENTS
Previous studies have documented the importance of a strong cellular immune response

in reducing tissue parasite burden and subsequent clinical pathology in humans and mice. Three
weeks after the final immunization and at the end of 8th week post infection challenge, in order to
compare cellular (Th1) immune responses four mice per experimental group were sacrificed via
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CO2 inhalation. These animals were used as source of tissue for post-mortem immunological,
and parasitological studies.
Multiparameter flow cytometry. 1.5 x 106 leukocytes from spleen or lymph node cells
were incubated with 10 µg/ml leishmania antigen and 2 µl/ml antibody to CD28 for 2 h at 37 oC.
Brefeldin A was added at final concentration of 10 µg/ml and cells were incubated for 4 hours.
To define T cell phenotype and intracellular cytokine staining, cells were incubated with the
viability dye ViViD, followed by staining for, CD4, IFN-γ, IL-2, and TNF-α using the BD
Cytofix/Cytoperm kit. Finally the cells were suspended in BD stabilizing fixative. A more
detailed description of the procedure is found in the Appendix portion.
Using the multiparameter flow cytometer and with assistance from Dr. Kristine Garza
and Ph.D. student Oscar Ramirez from the Biology department, quantification of cytokines was
determined. T cell percentage for both spleen and lymph nodes increased when comparing mice
groups 1A to 9. T lymphocytes are a major source of cytokines and bear antigen specific
receptors on their cell surface that allow for the recognition of foreign pathogens. CD4 and CD8
are two main subsets of T lymphocytes that assist in differentiating the presence of cell surface
molecules. For this study CD4 or T helper cells were the focus of the Th1 immune responses.
CD4 or T helper cells have no cytotoxic or phagocytic capabilities and cannot kill infected cells
or remove pathogens but are able to manage the immune responses by signaling other cells to
perform those tasks. It is therefore assumed that as footpad lesions became more inflamed due to
parasitic exposure, an increase in T cells were produced in response to the infection.
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Figure 3.16. % T cells for spleen samples in mice groups 1A–9.

Figure 3.17. % T cells for lymph node samples in mice groups 1A–9.
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Individual cytokines were quantified from the percentage of T cells that were detected by
the flow cytometer. Scattered and fluorescent light is picked up by the detectors and by
analyzing fluctuations in brightness at each detector, information about physical and chemical
structures were able to be determined for each individual particle. INF-γ, IL-2, and TNF-α were
measured and compared based on the treatment the mice received per group. Lymph node and
spleen cells were analyzed because lymph nodes are known to act as filters and trap particles
while becoming inflamed or enlarged when infection occurs. Lymph nodes are a good source of
lymphocytes that also help fight off infection and help in preventing infection by trapping
disease-causing germs. The spleen also contains high amounts of lymphocytes and macrophages
that engulf and destroy bacteria and in turn remove matter from the blood.
Cytokine quantification is graphed separately based on spleen and lymph node samples.
Th1 type cytokines are responsible for producing inflammatory responses that kill intracellular
parasites and for perpetuating autoimmune responses. High percentages of tumor necrosis factor
alpha (TNF-α) cytokines were seen in all groups due to natural killer cells being produced after
the parasite antigen involved since the early defense of Leishmania infection. TNF-α plays a
crucial role in the systemic inflammation that stimulates the acute phase reaction and is able to
induce apoptotic cell death to induce inflammation. This type of cytokine is produced mostly in
macrophages but also present in other types of cells. Interleukin-2 (IL-2) percentages are
significantly lower than TNF due to IL-2 being immediately used up by cells when exposed to an
infection. IL-2 stimulates the immune system and can lead to large increases in the number of
CD4 (T-helper) cells. IL-2 cytokines are able to differentiate between self and non-self foreign
materials and participate in the maintenance of regulatory T cells that maintain immune system
homeostasis. Interferon gamma (IFN-γ) is present when excessive pro-inflammatory responses

42

lead to uncontrolled tissue damage. Interferon gamma attempts to counteract this mechanism by
activating macrophages, which also leads to the activation of natural killer cells (NK), antigenspecific cytotoxic T lymphocytes and the release of cytokines in response to the antigen.
Cellular immunity protects the body against intracellular pathogens such as Leishmania by
activating antigen-specific cytotoxic T lymphocytes that are able to induce apoptosis of cells.
Mean intensity is also graphed as fluorescence emitted by cytokines and is a measurement of the
amount of cytokines that were produced.
As expected, mice treated with the cocktail vaccine produced a higher amount of
cytokines as opposed to those treated with the Cu/Zn lipid complex. The mean intensity studies
showed that the amount of cytokines produced by T cells was large compared to those with the
plasmids alone or with the controls. It is hypothesized that higher Th2 responses will be seen for
mice treated with lipid complex.

Figure 3.18. Cytokine quantification for spleen samples.
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Figure 3.19. Mean intensity for spleen samples.

Figure 3.20. Cytokine quantification for lymph node samples.
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Figure 3.21. Mean Intensity for lymph node samples.

In summary, Zn and Cu lipid complexes showed to have transfection capabilities in Hela,
COS1, and macrophages cell lines. Footpad lesion measurements revealed that the cocktail
vaccine resulted in a higher protection than mice groups treated with the metal lipid complexes
or with individual plasmids. Flow cytometric analysis confirmed that higher quantities of
cytokines were produced in mice groups treated with the cocktail vaccine and much lower
amounts for those treated with the lipid metal complexes. Overall, the cocktail vaccine showed
to have protective properties than any other treatment.
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Conclusions
The design and synthesis of molecules that self-organize in water to form functional
nanosystems were tested as drug delivery systems with a Leishmania vaccine. The design,
synthesis and functional activity of Cu(II) and Zn(II) complexes achieved the self-assemble in
water to form spherical nanoscale structures and were able to exhibit an affinity to bind DNA
when tested in agarose gels but were not as effective in the delivery of eukaryotic cells. We
investigated the ability of the Cu(II) and Zn(II) complexes to bind and deliver a gene vaccine
against Leishmania mexicana challenged with Leishmania major, into mice models and flow
cytometric analysis revealed the quantity of cytokines produced by T cells. The cocktail vaccine
showed a significant amount of protection when compared to the individual plasmid components
and the metallo-lipid nanoparticle treated mice.
We have accomplished our objectives to determine the efficacy of p-Vax-BT-ICAM,
and/or p-Vax-ORFF-Amastin plus metallo-liposomes in preventing murine leishmaniasis
infection and determine if metallo-liposomes possess adjuvant properties that enhance the innate
immune response. Future studies will analyze Th2 immune response with these metallo-lipid
nanoparticles as well as be tested with mice models challenged against Leishmania mexicana.
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Appendix

A.1.

SUPPORTING INFORMATION FOR CHAPTER 2
Synthesis of 1-dodecyl-1,4,7-triazacyclononane (TACN-C12). 0.1g of 1,4,7-

triazacyclononane, 0.19 g of 1-bromododecane, 0.02 g of NaH, and 1.6 equivalents of NaOH
were used for the reaction. 300 ml of THF were degassed and distilled by employing an Argon
environment for a few minutes. THF was then left heating at 60°C and left stirring
simultaneously. The first 50 ml of solution were disposed from a round bottom flask and first
200 ml of THF was collected and was degassed with Argon for a few minutes. 1,4,7triazacycononane was dissolved in dried THF in a round bottom flask and was left stirring and
heating at 60°C for the entire reaction. NaH was added and 1-bromododecane was dissolved
using 5 ml of THF in a 10 ml separatory funnel. This was added drop-wise to the 1,4,7triazacyclononane and THF solution; this approximately took 3-5 hours. The reaction was left
running for 24 hours and tracked by thin layer chromatography. TLCs were performed in order
to assure that the complex was pure. Ultimately, a yellow viscous oil was the result after
completion of the reaction. Chloroform was added in small amounts in order to weigh vial
containing the complex and was evaporated; weight was approximately 0.0167 g. Copper
triflate/zinc triflate was added in a 2:1 ratio. 0.0097 g of Cu/Zn(OTF)2 was suspended in 5 ml of
acetonitrile in a vial. 5 ml of acetonitrile was also added to the ligand in a vial and transferred to
a round bottom flask. Cu(OTF)2/Zn(OTF)2 was added drop-wise to the ligand under Argon
conditions for approximately 5 hours. The solution was transferred to a vial and all solvent was
evaporated. Once the Cu/Zn complexes were successfully synthesized they were suspended in
water for a 1.5 mM solution in water. Metal ligand complexes were rotovaped for 15 minutes in
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a 10 ml round bottom flask and 80 µl of chloroform with 500 µl of water was added. The
solution was sonicated until it appeared as a milky white solution and rotovaped once more for
15 minutes. That solution was transferred to a vial and brought to a final weight of 0.5 g. 400 µl
of the 1.5 µM solution was transferred to 600 µl of water and kept in a separate ependorf tube.
The desired amount of DNA (µg) was placed in a second eppendorf tube and brought to a final
volume of 1 ml by adding water. The two eppendorfs were combined and mixed and were
incubated for 15 minutes prior to immunization. This synthesis was good for 20 doses of 100 µl
each.
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A.2.

SUPPORTING INFORMATION FOR CHAPTER 3

A.2.1. Preparation of DNA Plasmids
LB Broth. LB broth was prepared by bringing a 500 ml container to 400 ml with DI
water. 5g of NaCl, 2.5 g of yeast, and 5 g of tryptone were mixed in the container and dissolved.
The container was brought to 500 ml of DI water and pH was measured (pH must be
approximately 7.4). Broth was autoclaved for 30 minutes, left to cool at room temperature.
Kanamycin Antibiotic. Kanamycin antibiotic aliquots were prepared by placing 0.25 g
of kanamycin into 10 ml of DI water. Contents were stirred and filtered using a syringe and
stored in eppendorf tubes where they were stored until use in a 4°C freezer.
Bacterial Growth. 500 µl of kanamycin antibiotic were added to a 500 ml glass
container containing LB broth and swirled. 100 µl of desired bacterial plasmid was added,
capped loosely and placed in a 37°C incubator overnight.

A.2.2. Purification of DNA
Wizard Plus Maxipreps DNA Purification System. Maxipreps were performed in
order to isolate the plasmid DNA from the bacteria. In order to precipitate both DNA and
proteins, the bacteria was lysed under alkaline conditions. Preparation of the clear lysate was
accomplished by pelting cells at 5,000 x g for 10 minutes at room temperature. Pellet was
suspended in 10 ml Cell Resuspension Solution. 10 ml Cell Lysis Solution was added and
inverted to mix. 10 ml of Neutralization Solution was added and inverted to mix. Lysate was
centrifuged at 14,000 x g for 15 minutes. Supernatant was filtered into a graduated cylinder and
volume was measured and liquid was transferred to centrifuge bottle. 0.5 volume isopropanol
58

was added and inverted to mix. Contents were centrifuged at 14,000 x g for 15 minutes and
pellet was resuspended in 2 ml of TE buffer. When purifying plasmid DNA, resin was
resuspended and 10 ml of resin were added to DNA and swirled. Maxicolumn was attached to
vacuum manifold and resin/DNA mixture was transferred to Maxicolumn. Vacuum was applied,
releasing all liquid from the column. Washing was accomplished by adding 25 ml of Column
Wash Solution containing ethanol. Vacuum was applied, pulling liquid through column.
Vacuum was released and 5 ml of 80% ethanol was added. Vacuum was again applied and
continued for 1 minute after liquid passed through Maxicolumn. Maxicolumn was transferred to
a 50 ml centrifuge tube. It was centrifuged at 1,300 x g for 5 minutes, using a swinging bucket
rotor. Maxicolumn was placed on manifold and vacuum was applied for a final time for 5
minutes. Maxicolumn was placed in Reservoir tube and 1.5 ml of preheated water was added.
After 1 minute, it was centrifuged at 1,300 x g for 5 minutes to elute DNA. Eluted DNA was
filtered and centrifuged filtrate at 14,000 x g for 1 minute. Supernatant containing DNA was
transferred to a new centrifuge tube and stored at -20˚C or below.

A. 2.3. cDNA Synthesis
cDNA Synthesis Directly from Cells Using SuperScriptTM III CellDirect cDNA
Synthesis System. The SuperScript™ III CellsDirect cDNA Synthesis System is an optimized
kit for synthesizing first-strand cDNA directly from mammalian cell lysate without first isolating
the RNA. Lysis and reverse transcription were performed in the same tube, and the resulting
first-strand cDNA was ready to use in cloning and PCR.
In traditional RT-PCR, RNA is first isolated from cells in a time-consuming procedure
that can lead to a loss of material. Using the SuperScript™ III CellsDirect cDNA Synthesis
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System, the cells are lysed and the cDNA is generated from the lysate in a single tube with
minimal handling and no sample loss. DNase I is added to eliminate genomic DNA prior to firststrand synthesis.
Cells were grown in tissue culture wells with Cu/Zn complexes along with combinations
of the four antigens that compose Leishmania and the following procedure was used to lyse the
cells. Media was aspirated from each well and washed with 1X cold PBS. PBS was aspirated
and Resuspension Buffer/Lysis Enhancer solution was added to each well. The buffer should
fully cover the cells in the well. The plates were incubated on ice for up to 10 minutes and
during this time, the plate was periodically tapped and cells were checked under a microscope
every 2-3 minutes to see whether they had detached or burst. After 10 minutes, the cells were
pipetted up and down to dislodge the remaining attached cells. Cells were counted using a
hemacytometer and 10 µl of cell suspension was transferred to 0.2-ml thin-walled PCR tubes. 1
µl of RNaseOUTTM was added to the PCR tubes. The tubes were transferred to the thermal
cycler preheated to 75°C and incubated for 10 minutes. After incubation, the tubes were spun
briefly to collect the condensation. The cell lysate was then treated with DNase I to degrade any
contaminating DNA by placing each tube on ice and adding 5 µl DNase I and 1.6 µl 10X DNase
I Buffer. All contents were mixed gently and pipetted up and down and spun briefly. Tubes
were incubated for 5 minutes at room temperature, spun briefly, and 1.2 µl of 25 mM EDTA was
pippetted to each while on ice. Contents were again mixed, pipetted up and down, and spun
briefly followed by another incubation period of 5 minutes at 70°C. Tubes were spun and first
strand of cDNA synthesis was begun. Each tube was pippetted with 2 µl of Oligo(dT)20 (50µM)
and 1 µl of 10 mM dNTP mix. They were again mixed gently and pipetted up and down
followed by a quick spin. Tubes were incubated at 70°C for 5 minutes and spun to collect the
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condensation. They were then placed on ice for 2 minutes and were pipetted with 6 µl of 5X RT
Buffer, 1 µl of RNaseOUTTM, 1 µl of SuperScriptTM III RT, and 1 µl of 0.1 M DTT. Tubes were
mixed and pipetted up and down and spun to collect contents and were transferred to the thermal
cycler preheated to 50°C. They were incubated for 50 minutes at this temperature and switched
to 85°C for 5 minutes to inactivate the reaction. 1 µl of RNase H was pipetted to each tube and
incubated at 37°C for 20 minutes. The reaction was chilled on ice and the single stranded cDNA
was stored at -20°C.

A. 2.4. Polymerase Chain Reaction (PCR)
PCR. PCR was utilized in order to exponentially amplify the DNA template. Four
flasks of cells were infected with Leishmania and were trypsinized and their DNA was purified
using protocol: DNA Purification from Cultured Cells Using the Gentra Puregene Cell Kit. This
was used as the positive control when running the gel to assure that the DNA was present and
being expressed. The objective was to amplify 4 genes (ICAM-1, BT, ORFF, and Amastin, all of
which are from the Leishmania genome). In order to copy, primers were utilized, two primers
one on each end of the original strand of DNA (one in the 3’ end and the other at the 5’ end).
The DNA was denatured in order to separate the double helical strand; the chain was then
copied. In an agarose gel, the four genes were amplified, all in their own specific size. The
DNA ladder was placed in the gel in order to determine the different DNA sizes and the number
of base pairs. Materials utilized for PCR included 1 µl Leishmania DNA (served as the template
with a concentration of 677.9 ng/µl), 12.5 µl master mix (comprised of Mg, DNTP, DNA
polymersase), 1 µl reverse primer, 1 µl forward primer, and nuclease free water. If the amount of
primers was decreased, nuclease free water was increased to compensate for the loss such as
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when running ORFF (0.7 µl of primers were used). All contents were combined in PCR 100 µl
tubes, vortexed, and centrifuged for a few seconds so that all contents collected at the bottom of
tube. Genes ran under the following conditions in a thermal cycler:
BT
95 C for 30s
95 C for 30s
60 C for 30s
72 C for 1m 50s
72 C for 10m
ICAM
95 C for 30s
95 C for 30s
60 C for 30s
72 C for 1:45

35X

35X

ORFF
95 C for 30s
95 C for 30s
56 C for 30s
72 C for 1m
Amastin
95 C for 30s
95 C for 30s
60 C for 30s
72 C for 1m

35X, used 0.7 µl primers

35X

PCR tubes were quickly removed and place in ice after completion of cycles. 2 µl of dye
was pipetted into each sample, vortexed, and centrifuged and loaded into an agarose gel.

Agarose Gel Preparation. 0.504 g of agarose were weighed and added to 84 ml of TAE
1X buffer in an Erlenmeyer flask. Contents were heated until agarose was fully dissolved and 2
µl of Ethidium Bromide was pipetted, and swirled in flask. Gel was poured in gel
electrophoresis apparatus and left to solidify.

A. 2.5. Protein Determination
Bicinchoninic Acid Protein Assay Kit. Protein determination is one of the most
common operations performed in biochemical research. The principle of the bicinchoninic acid
(BCA) assay is similar to the Lowry procedure. In that both rely on the formation of a Cu2+
protein complex under alkaline conditions, followed by reduction of the Cu2+ to Cu1+. The
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amount of reduction is proportional to the protein present. It has been shown that cysteine,
cystine, tryptophan, tyrosine, and the peptide bond are able to reduce Cu2+ to Cu1+. BCA forms
a purple-blue complex with Cu1+ in alkaline environments, thus providing a basis to monitor the
reduction of alkaline Cu2+ by proteins.
The BCA working reagent was prepared combining 25 ml of Bicinchoninic Acid solution
and 500 µl of Cu(II) Sulfate solution. Dilutions were prepared in test tubes and numbered
accordingly – (1) 100 µl DI water, (2) 80 µl DI water + 20 µl Protein Standard, (3) 60 µl DI
water + 40 µl Protein Standard, (4) 40 µl DI water + 60 µl Protein Standard, (5) 20 µl DI water +
80 µl Protein Standard, (6) 100 µl Protein Standard, (7) 80 µl DI water + 20 µl L. mexicana
antigen, (8) 40 µl DI water + 60 µl L. mexicana antigen, (9) 100 µl L. mexicana antigen, (10) 80
µl DI water + 20 µl L. major antigen, (11) 40 µl DI water + 60 µl L. major antigen, and (12) 100
µl L. major antigen. All samples were incubated at 37°C for 30 minutes and allowed to cool at
room temperature. All samples were then transferred to a cuvet and their absorbance was
measure in order to calculate concentration.

A. 2.6. Mice Protocols
Intramuscular Injection of Mouse. A 22- and 30-G needle syringe was used for
immunizations. Animal was placed in a trap and restrained; needle was inserted in the heavy
muscularture of the lower posterior leg. Syringe was aspirated briefly before injecting to prevent
intravenous or intra-arterial injection. Moderate pressure was placed when injecting to avoid
tissue damage.

Euthanasia. Methods of euthanasia should be painless, quick, easy to perform, safe for
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those performing the procedure, efficient, economic and minimize distress. Methods should not
result in gross histological or histochemical changes that would adversely affect research results.
Carbon dioxide asphyxiation was used in the study and utilized in all rodents. Animals were
placed in CO2 chamber and lid was placed. A hose connected to a CO2 tank was fed through an
opening in the chamber and slowly turned on. Animal was left in chamber for approximately a
minute and death was verified by lack of cardiac pulse and dilated pupils.

A. 2.7. Flow Cytometry
BD Cytofix/Cytoperm Kit. Lymph nodes and spleen were grinded with RPMI media
containing Fetal Bovine Serum and Streptomycin. Spleen cells were transferred to a 15 ml
conical tube in order to remove tissue solids. 5 ml of Lysis Buffer was added at room
temperature and left incubating for 4 minutes with occasional shaking. The reaction was
terminated by diluting the Lysis Buffer with 30 ml of 1X PBS and centrifuged for 10 minutes.
Supernatant was removed and 1 ml of fresh media was added. Lymph nodes were also
transferred to a 15 ml conical tube in order to remove tissue solids. Conical tube was centrifuged
for 2 minutes and 1 ml of fresh media was added. Both spleen and lymph node cells were
counted and plated in a 96 well plate with 106 cells/well. Cells were incubated with 0.5 µl of
CD28 and 1 µl of Leishmania major antigen/well for 2 h at 37ºC. 0.2 µl of BD GolgiPlug was
added per well, mixed, and incubated for 4 h. The plate was centrifuged and BD GolgiPlug
containing media was removed. 50 µl of Staining Buffer and 1.25 µl CD4 were added per well
and incubated for 30 minutes at 4ºC. Cells were centrifuged for 10 minutes, washed twice with
Staining Buffer and centrifuged. Cells were resuspended and 100 µl of
Fixation/Permeabilization solution was added per well and left incubating for 20 minutes at 4ºC.
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Cells were centrifuged for 10 minutes, washed twice in 1xBD Perm/Wash buffer and 200 µl of
1xBD Perm/Wash buffer was added in addition to 2 µl of TNF-α-FITC, 2 µl of IL-2-PE, and 1 µl
of IFN-γ per respective well. Plate was left incubating for 30 minutes at 4ºC. Cells were
centrifuged for 10 minutes and cells were washed once with 1xBD Perm/Wash buffer. 0.3 µl of
Texas Red were added to wells containing TFN and left incubating for 30 minutes at 4ºC. Cells
were centrifuged for 10 minutes, washed twice with 1xBD Perm/Wash buffer and resuspended in
200 µl of Staining Buffer prior to flow cytometric analysis. If analysis did not follow
immediately, cells were resuspended in 4% paraformaldehyde, covered with aluminum foil to
avoid direct light and left in 4ºC.

A. 2.8. Culturing Macrophages and Footpad Lesions
Macrophages. Macrophages were collected from rodents in 50 ml conical tube. Cells were
centrifuged for 10 minutes at room temperature. Media was removed leaving only 1 ml of media
with cells. Cells were counted and 106 cells/well were plated in a 24 well plate. 500 µl of RPMI
media containing Fetal Bovine Serum and Streptomycin was added to each well. Cells were left
to incubate overnight to assure proper adhesion and washed every two days. Washing was
performed by removing media from wells and replaced with RPMI media (without FBS and
Streptomycin). Cells were resuspended with 1.5 ml of RPMI media containing FBS and
Streptomycin.

Mice Footpad Lesions. Eppendorfs containing 1 ml RMPI media (containing FBS and
Streptomycin) were previously weighed. Footpad lesions were grinded and placed in eppendorf
and weighed once more to calculate weight of tissue. Cells received 10 µl of additional
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Streptomycin and 150 µl of media containing cells were plated per well. All wells received 150
µl media. Dilutions were made beginning with 300 µl in first well, reduced to 150 µl to second
well and so on and so forth. Plate was incubated at room temperature for one week.
A. 2.9. RNA/cDNA
RNA Homogenization/Extraction/Purification. Excess cells from lymph nodes and
spleen was utilized. Cells were homogenized in 1ml TRI Reagent per 106 suspension culture
cells. Homogenate was incubated for 5 minutes at room temperature. Cells were centrifuged
12,000 x g for 10 minutes at 4ºC and supernatant was transferred to a new tube. 1 ml of
homogenate was transferred to a labeled 1.5 ml microcentrifuge tube. 200 µl of chloroform was
added per tube and vortexed at maximum speed for 15 seconds. Tubes were incubated at room
temperature for 5 minutes and centrifuged at 12,000 x g for 10 minutes at 4ºC. 400 µl of top
layer was transferred to a new 1.5 ml microcentrifuge tube. 200 µl of 100% ethanol was added
and vortexed for 5 seconds. Sample was passed through a filter cartridge and centrifuged at
12,000 x g for 30 seconds at room temperature. Flow through was discarded and filter was
returned to cartridge. 500 µl of Wash Solution was added to filter cartridge-collection tube
assembly. Assembly was centrifuged for 30 seconds at room temperature and flow through was
once more discarded and returned to original collection tube. Wash was done once more
followed by centrifugation for 30 seconds at room temperature. Filter cartridge was placed in a
new collection tube and 50 µl of Elution Buffer was added to filter column. Incubation at room
temperature for 2 minutes followed. Filter column was centrifuged for 30 seconds to elute the
RNA from the filter.
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cDNA Reverse Transcription Reaction. 10 µl of 2X RT master mix was pipetted into
each individual tube. 10 µl of RNA sample was added into each tube and pipetted up and down.
Tubes were centrifuged briefly to spin down contents and to eliminate air bubbles. Tubes were
placed on ice until loading into thermal heater.
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